Phase 3 Readout~month

Phase 3 Topline: IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as Fi

Indication
Metastatic Uveal Melanoma

Other upcoming events for IDYA

Phase 3 ReadoutPhase 3 Topline: Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenf
Phase 3 ReadoutPhase 3 Topline: A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-met

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as Fi — IDYA Phase 3 Readout | BioSniper